Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 14:50:e20233482.
doi: 10.1590/0100-6991e-20233482-en. eCollection 2023.

Smoking cessation for peripheral arterial disease: systematic review protocol

[Article in English, Portuguese]
Danielle Akemi Bergara Kuramoto  1 , Luiz Fernando Santetti Zanin  1 , Ronald Luiz Gomes Flumignan  1 , Carolina Dutra Queiroz Flumignan  1 , Marcello Erich Reicher  1 , Rebeca Mangabeira Correia  1 , Luís Carlos Uta Nakano  1
Affiliations

Smoking cessation for peripheral arterial disease: systematic review protocol

[Article in English, Portuguese]
Danielle Akemi Bergara Kuramoto et al. Rev Col Bras Cir. .

Abstract
in English, Portuguese

Background: peripheral arterial disease has smoking as its main avoidable vascular risk factor. However, most studies do not focus on smoking as the main exposure variable.

Objectives: to assess the impact of smoking cessation interventions versus active comparator, placebo or no intervention, on peripheral arterial disease outcomes.

Methods: we will use the Cochrane Handbook for Systematic Reviews of Interventions to guide whole this review process. We will consider parallel or cluster-randomised controlled trials (RCTs), quasi-RCTs, and cohort studies. We will search CENTRAL, MEDLINE, Embase, PsycINFO, LILACS and IBECS. We will also conduct a search of ClinicalTrials.gov and the ICTRP for ongoing or unpublished trials. Each research step will involve at least two independent reviewers. We will create a table, using GRADE pro GDT software, reporting the pooled effect estimates for the following outcomes: all-cause mortality, lower limb amputation, adverse events, walking distance, clinical severity, vessel or graft secondary patency, and QoL.

Conclusions: we will assess these outcomes according to the five GRADE considerations to assess the certainty of the body of evidence for these outcomes, and to draw conclusions about the certainty of the evidence within the review.

Introdução:: a doença arterial periférica tem o tabagismo como principal fator de risco vascular evitável. Entretanto, a maioria dos estudos não destaca o tabagismo como principal variável de exposição.

Objetivos:: avaliar o impacto das intervenções de cessação do tabagismo versus comparador ativo, placebo ou nenhuma intervenção, nos desfechos da doença arterial periférica.

Métodos:: usaremos o Cochrane Handbook for Systematic Review of Interventions para orientar todo este processo de revisão. Consideraremos ensaios controlados paralelos ou randomizados por cluster (ECRs), quase-ECRs e estudos de coorte. Buscaremos no CENTRAL, MEDLINE, Embase, PsycINFO, LILACS e IBECS. ClinicalTrials.gov e ICTRP serão consultados para ensaios em andamento ou não publicados. Criaremos uma tabela, usando o software GRADE pro GDT, relatando as estimativas de efeito agrupado para os seguintes desfechos: mortalidade por todas as causas, amputação de membro inferior, eventos adversos, distância percorrida, gravidade clínica, permeabilidade secundária do vaso ou enxerto e qualidade de vida. Avaliaremos esses resultados de acordo com as cinco considerações GRADE para avaliar a certeza do corpo de evidências para esses resultados e tirar conclusões sobre a certeza das evidências na revisão.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: no.

References

    1. World Health Organization Organization World Health. https://apps.who.int/iris/handle/10665/330221 WHO global report on trends in prevalence of tobacco use 2000-2025. 2019
    1. Fagerström K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002;62:1–9. doi: 10.2165/00003495-200262002-00001. - DOI - PubMed
    1. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet Lond Engl. 2013;382(9901):1329–1340. doi: 10.1016/S0140-6736(13)61249-0.. - DOI - PubMed
    1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509–1526. doi: 10.1161/CIRCRESAHA.116.303849. - DOI - PubMed
    1. Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32(4):328–333. doi: 10.1016/j.amepre.2006.12.010. - DOI - PubMed

LinkOut - more resources